FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385069258> ?p ?o ?g. }

• W4385069258 endingPage "181" @default.
• W4385069258 startingPage "166" @default.
• W4385069258 abstract "Introduction. There are several forms of the L-asparaginase which are characterized by differences in the half-life, the spectrum of toxicity as well as other factors. Aim — to determine the incidence of different types of L-asparaginase toxicity in adult patients with Ph-negative acute lymphoblastic leukemia (ALL) treated according to the ALL-2016 protocol. Materials and methods . From December 2016 to February 2023 the multicenter prospective randomized study “ALL-2016” included 313 patients with newly diagnosed Ph-negative ALL. Information about the 256 patients who had toxicity of native L-asparaginase was entered into an electronic database. The ratio of men and women was 155:101. The median age was 32 (18–54) years. We analyzed 1253 courses of therapy that included the administration of L-asparaginase. Results . L-asparaginase toxicity and adverse reactions were diagnosed in 67 (26 %) of 256 patients. Of the 1253 courses, 102 (8 %) had complications associated with the administration of this drug. Grade 1–2 toxicity of L-asparaginase was diagnosed in 34 (51 %) patients: allergic reaction — in 6 (18 %), thrombosis of brachiocephalic veins associated with the installation of a central venous catheter — in 2 (6 %), increased pancreatic amylase in blood serum and diastase in urine, without clinical signs of pancreatitis — in 3 (9 %), lower protein-synthesis function of liver — in 23 (68 %), hepatotoxicity — in 15 (44 %). Grade 3–4 toxicity of L-asparaginase was diagnosed in 33 (49 %) patients, of which 22 (67 %) required discontinuation of the drug. The median of the development of complications of L-asparaginase was the third administration. None of the patients died as the result of the toxicity of native form of the drug. The 5-year overall survival (OS) and the probability of relapse (PR) in the group of patients in which L-asparaginase was discontinued at the stage of induction of remission and in the group of patients who continued L-asparaginase treatment at remission consolidation and maintenance therapy did not differ significantly: OS — 89 % vs 70 % (p = 0.0921), PR — 47 % vs 33 % (р = 0.8633). Conclusion. In adult patients, L-asparaginase withdrawal due to toxicity, in most cases, occurs at the stage of the remission induction. It is possible that the replacement of the native form the drug to the pegylated one in adult patients with ALL, in whom L-asparaginase is canceled at the stage of remission induction, improves long-term survival rates." @default.
• W4385069258 created "2023-07-23" @default.
• W4385069258 creator A5004167682 @default.
• W4385069258 creator A5005294423 @default.
• W4385069258 creator A5008276842 @default.
• W4385069258 creator A5009453463 @default.
• W4385069258 creator A5023446963 @default.
• W4385069258 creator A5025150256 @default.
• W4385069258 creator A5044776670 @default.
• W4385069258 creator A5048111911 @default.
• W4385069258 creator A5055554989 @default.
• W4385069258 creator A5080998304 @default.
• W4385069258 date "2023-07-17" @default.
• W4385069258 modified "2023-09-26" @default.
• W4385069258 title "The use of pegaspargase in adult Ph-negative acute lymphoblastic leukemia patients in the treatment according to the all-2016 protocol" @default.
• W4385069258 cites W1483201954 @default.
• W4385069258 cites W1595924202 @default.
• W4385069258 cites W17959953 @default.
• W4385069258 cites W1879221139 @default.
• W4385069258 cites W1887863677 @default.
• W4385069258 cites W1939497674 @default.
• W4385069258 cites W1940732706 @default.
• W4385069258 cites W1944430150 @default.
• W4385069258 cites W1966375226 @default.
• W4385069258 cites W1977546984 @default.
• W4385069258 cites W1984160435 @default.
• W4385069258 cites W1989771063 @default.
• W4385069258 cites W2008009748 @default.
• W4385069258 cites W2017072037 @default.
• W4385069258 cites W2018184592 @default.
• W4385069258 cites W2024777863 @default.
• W4385069258 cites W2037037639 @default.
• W4385069258 cites W2037808957 @default.
• W4385069258 cites W2040730344 @default.
• W4385069258 cites W2044461258 @default.
• W4385069258 cites W2047657755 @default.
• W4385069258 cites W2049552282 @default.
• W4385069258 cites W2052739233 @default.
• W4385069258 cites W2056562985 @default.
• W4385069258 cites W2056667876 @default.
• W4385069258 cites W2067585473 @default.
• W4385069258 cites W2080051364 @default.
• W4385069258 cites W2117623554 @default.
• W4385069258 cites W2127153931 @default.
• W4385069258 cites W2146762986 @default.
• W4385069258 cites W2150552945 @default.
• W4385069258 cites W2163219205 @default.
• W4385069258 cites W2164520862 @default.
• W4385069258 cites W2166295047 @default.
• W4385069258 cites W2485785171 @default.
• W4385069258 cites W2512094133 @default.
• W4385069258 cites W2765434048 @default.
• W4385069258 cites W2766142559 @default.
• W4385069258 cites W2770856392 @default.
• W4385069258 cites W2903270680 @default.
• W4385069258 cites W2908746540 @default.
• W4385069258 cites W2914373601 @default.
• W4385069258 cites W2980437134 @default.
• W4385069258 cites W3001275089 @default.
• W4385069258 cites W3015698333 @default.
• W4385069258 cites W3095135008 @default.
• W4385069258 cites W3133547570 @default.
• W4385069258 cites W3155294922 @default.
• W4385069258 cites W3188538004 @default.
• W4385069258 cites W4211046582 @default.
• W4385069258 cites W4226119270 @default.
• W4385069258 cites W4234454654 @default.
• W4385069258 cites W426270985 @default.
• W4385069258 doi "https://doi.org/10.35754/0234-5730-2023-68-2-166-181" @default.
• W4385069258 hasPublicationYear "2023" @default.
• W4385069258 type Work @default.
• W4385069258 citedByCount "0" @default.
• W4385069258 crossrefType "journal-article" @default.
• W4385069258 hasAuthorship W4385069258A5004167682 @default.
• W4385069258 hasAuthorship W4385069258A5005294423 @default.
• W4385069258 hasAuthorship W4385069258A5008276842 @default.
• W4385069258 hasAuthorship W4385069258A5009453463 @default.
• W4385069258 hasAuthorship W4385069258A5023446963 @default.
• W4385069258 hasAuthorship W4385069258A5025150256 @default.
• W4385069258 hasAuthorship W4385069258A5044776670 @default.
• W4385069258 hasAuthorship W4385069258A5048111911 @default.
• W4385069258 hasAuthorship W4385069258A5055554989 @default.
• W4385069258 hasAuthorship W4385069258A5080998304 @default.
• W4385069258 hasBestOaLocation W43850692581 @default.
• W4385069258 hasConcept C126322002 @default.
• W4385069258 hasConcept C141071460 @default.
• W4385069258 hasConcept C2778461978 @default.
• W4385069258 hasConcept C2778715236 @default.
• W4385069258 hasConcept C2778904437 @default.
• W4385069258 hasConcept C2909962599 @default.
• W4385069258 hasConcept C29730261 @default.
• W4385069258 hasConcept C71924100 @default.
• W4385069258 hasConcept C90924648 @default.
• W4385069258 hasConceptScore W4385069258C126322002 @default.
• W4385069258 hasConceptScore W4385069258C141071460 @default.
• W4385069258 hasConceptScore W4385069258C2778461978 @default.
• W4385069258 hasConceptScore W4385069258C2778715236 @default.
• W4385069258 hasConceptScore W4385069258C2778904437 @default.

• next